Wells Fargo Sees Strong Upside in Tandem Diabetes After Fast Pharmacy Progress
Wells Fargo upgraded Tandem Diabetes, raising price target to $27 on strong growth, better pharmacy model, and positive outlook.
/ 2 items
Wells Fargo upgraded Tandem Diabetes, raising price target to $27 on strong growth, better pharmacy model, and positive outlook.
Piper Sandler upgrades Tandem Diabetes to Overweight from Neutral, raises PT to $33 from $21. Mobi pump, pharmacy pricing, and international growth drive revenue upside.